Claims
- 1. An antibacterial mixture comprising a synergistically effective amount of the compound of the formula (I): ##STR6## or a pharmaceutically acceptable salt thereof and an antibacterially effective amount of a compound of the formula (III): ##STR7## or a pharmaceutically acceptable salt thereof wherein R.sup.1 is hydrogen or hydroxyl, in a weight ratio of from 1:1 to 1:15.
- 2. A mixture according to claim 1 wherein R.sup.1 is hydroxyl.
- 3. A mixture according to claim 1 wherein the compounds of the formulae (I) and (III) or their salts are present in the ratio of from 1:1 to 1:15 by weight.
- 4. A mixture according to claim 1 wherein the compounds of the formulae (I) and (III) or their salts are present in the ratio of from 1:3 to 1:10 by weight.
- 5. A mixture according to claim 1 in unit dose form comprising from 25 to 250 mg of a salt of the compound of the formula (I) and from 62.5 to 2500 mg of a salt of the compound of the formula (III).
- 6. A mixture according to claim 1 wherein R.sup.1 is hydrogen.
- 7. A mixture according to claim 1 wherein clavulanic acid is in the form of the sodium salt and the compound of the formula (III) is the sodium salt of the formula: ##STR8##
- 8. A mixture according to claim 1 wherein the compounds of the formulae (I) and (III) are in the form of pharmaceutically acceptable salts.
- 9. A mixture according to claim 8 wherein the compounds of the formulae (I) and (III) are in the form of their sodium salts.
- 10. A mixture according to claim 8 adapted for parenteral administration.
- 11. A pharmaceutical composition for treating bacterial infections in humans and animals which comprises a synergistically effective amount of clavulanic acid or a pharmaceutically acceptable salt thereof and an antibacterially effective amount of a compound of the formula (III): ##STR9## or a pharmaceutically acceptable salt thereof wherein R.sup.1 is hydrogen or hydroxyl, in a weight ratio of 1:1 to 1:15, in combination with a pharmaceutically acceptable carrier.
- 12. A composition according to claim 4 wherein the weight ratio is 1:1 to 1:15.
- 13. A composition according to claim 11 wherein the weight ratio is 1:2 to 1:12.
- 14. A composition according to claim 11 wherein the weight ratio is 1:3 to 1:10.
- 15. A composition according to claim 11 wherein clavulanic acid and the compound of formula (III) are each in the form of a pharmaceutically acceptable salt.
- 16. A composition according to claim 11 wherein clavulanic acid is in the form of a pharmaceutically acceptable salt and the compound of formula (III) is in the form of the sodium salt.
- 17. A composition according to claim 11 wherein clavulanic acid and the compound of the formula (III) are each in the form of the sodium salt.
- 18. A composition according to claim 11 wherein R.sup.1 is hydrogen.
- 19. A composition according to claim 11 wherein R.sup.1 is hydroxyl.
- 20. A composition according to claim 11 in parenteral administration form.
- 21. A composition according to claim 11 wherein clavulanic acid is in the form of the sodium salt and the compound of the formula (III) is the sodium salt of the formula: ##STR10##
- 22. A method of treating bacterial infections in humans and animals which comprises parenterally administering to a human or animal in need thereof a synergistically effective amount of clavulanic acid or a pharmaceutically acceptable salt thereof and an antibacterially effective amount of a compound of the formula (III): ##STR11## or a pharmaceutically acceptable salt thereof wherein R.sup.1 is hydrogen or hydroxyl in a weight ratio of 1:1 to 1:15.
- 23. A method according to claim 22 wherein the weight ratio is 1:1 to 1:15.
- 24. A method according to claim 22 wherein the weight ratio is 1:2 to 1:12.
- 25. A method according to claim 22 wherein the weight ratio is 1:3 to 1:10.
- 26. A method according to claim 22 wherein the clavulanic acid and the compound of formula (III) are each in the form of a pharmaceutically acceptable salt.
- 27. A method according to claim 22 wherein clavulanic acid is in the form of a pharmaceutically acceptable salt and the compound of formula (III) is in the form of the sodium salt.
- 28. A method according to claim 22 wherein clavulanic acid and the compound of the formula (III) are each in the form of the sodium salt.
- 29. A method according to claim 22 wherein R.sup.1 is hydrogen.
- 30. A method according to claim 22 wherein R.sup.1 is hydroxyl.
- 31. A method according to claim 22 wherein clavulanic acid is in the form of the sodium salt and the compound of the formula (III) is the sodium salt of the formula: ##STR12##
- 32. A composition according to claim 22 in unit dosage form wherein each dosage unit comprises 25 to 250 mg. of a pharmaceutically acceptable salt of clavulanic acid and from 6.25 to 2500 mg. of a pharmaceutically acceptable salt of the compound of formula (III).
- 33. A method of treating bacterial infections in humans and animals which comprises administering to said humans or animals an antibacterially effective amount of D-.alpha.-[(imidazolidin-2-oxo-1-yl)carbonylamino]-benzylpenicillin and clavulanic acid in a weight ratio of 1:1.
Priority Claims (1)
Number |
Date |
Country |
Kind |
26689/76 |
Jun 1976 |
GBX |
|
CROSS-REFERENCE
This is a continuation of Ser. No. 887,843 filed Mar. 17, 1978 now abandoned which is a continuation of Ser. No. 804,998 filed June 9, 1977, now abandoned.
Non-Patent Literature Citations (3)
Entry |
Chemical Abstracts 77: 126629v, (1972). |
Chemical Abstracts 81: 63616y, (1974). |
Derwent Farm Doc. #72840/w/44/, Abstracting DT 2517316, published 10/23/75. |
Continuations (2)
|
Number |
Date |
Country |
Parent |
887843 |
Mar 1978 |
|
Parent |
804998 |
Jun 1977 |
|